-
摘要:
目的 探讨硼替佐米+环磷酰胺+地塞米松（PCD方案）和长春新碱+表阿霉素+地塞米松（VAD方案）治疗多发性骨髓瘤的临床疗效及不良反应。 方法 回顾天津市第一中心医院血液科2011年1月至2013年1月收治的多发性骨髓瘤患者41例，依治疗方案不同分为PCD组及VAD组，分析两组患者的疗效及不良反应。 结果 PCD组治疗后部分缓解及以上的有效率达42.9%，而VAD组仅15.0%，差异有统计学意义（P < 0.05），在初治患者中反应良好的患者（CR和VGPR）PCD组为50.0%，VAD组7.7%，差异有统计学意义（P < 0.05），两组患者在疱疹感染、血细胞减少及乏力腹胀等方面的不良反应无明显差异，但PCD组的神经毒性的发生率较VAD组高，差异有统计学意义（P < 0.05）。 结论 PCD方案治疗多发性骨髓瘤疗效优于VAD方案，特别是对于初治患者PCD方案能明显提高缓解率，但治疗过程中应注意硼替佐米的神经毒性，必要时应减量应用。 Abstract:Objective To compare the efficacy and adverse effects of bortezomib+cyclophosphamide+dexamethasone (PCD) and vincristine+adriamycin+dexamethasone (VAD) regimens in multiple myeloma (MM). Methods A total of 41 patients with MM were analyzed retrospectively and divided into two groups according to their treatment protocols: PCD group (21 cases) and VAD group (20 cases). Clinical effects and adverse effects were observed in both groups. Patients accepted two to four cycles of PCD or VAD regimens. Results In the PCD group, three patients achieved complete remission (CR), three patients had very good partial remission (VGPR), three patients were under partial remission (PR), eight patients had stable disease status (SD), and four patients had progressive disease (PD). In the VAD group, none achieved CR, one patient had VGPR, two patients were under PR, nine patients had SD status, and nine patients had PD. The rate of patients who achieved efficacy (CR+VGPR+PR) in the PCD group was 42.9%, which was higher than that of the VAD group (15.0%). The rate of newly diagnosed patients who achieved good efficacy (CR+VGPR) in the PCD group was 50%, which was higher than that of the VAD group (7.7%). The incidence of herpes infection, cytopenia, fatigue, and gastrointestinal symptoms was similar in the two groups, whereas the incidence of neurotoxicity in the PCD group was higher than that of the VAD group. Conclusion The response rate of PCD is higher compared with that of conventional VAD chemotherapy, especially in newly diagnosed MM. PCD may improve CR and VGPR rates and may bring about more severe toxicities, such as neuropathy. -
Key words:
- multiple myeloma /
- therapy /
- adverse effects
-
表 1 两组患者的一般资料比较
Table 1. Comparison of baseline information of two groups
表 2 两组患者的总体疗效比较 例（%）
Table 2. Comparison of overall response rates of two groups n (%)
表 3 两种方案对初治患者的疗效比较 例（%）
Table 3. Efficacy comparison of newly diagnosed patients in the two groups n (%)
表 4 两种方案对复发难治患者的疗效比较 例（%）
Table 4. Efficacy comparison of relapsed/refractory patients in the two groups n (%)
-
[1] Mckenna RW, Kyle RA, Kuehl WM, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues[M]. Lyon: IARC Press, 2008:200-208. [2] 中国医师协会血液科医师分会, 中华医学会血液学分会.中国多发性骨髓瘤诊治指南[J].中华内科杂志, 2013, 52(9):791-795. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk200810035The Chinese medical doctor association branch of haematology department physicians, hematology branch of Chinese Medical Association. Diagnosis and treatment guideline of multiple myeloma in China [J]. Chinese Journal of Internal Medicine, 2013, 52(9):791-795. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk200810035 [3] Ludwig H, Beksac M, Blade J, et al. Current Multiple MyelomaTreatment Strategies with Novel Agents: A European Perspective[J]. Oncologist, 2010, 15(1):6-25. doi: 10.1634/theoncologist.2009-0203 [4] Moreau P, Attal M, Pegourie B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial[J]. Blood, 2011, 117(11):3041-3044. doi: 10.1182/blood-2010-08-300863 [5] 梁赜隐, 任汉云, 岑溪南, 等.硼替佐米为基础的化疗方案治疗多发性骨髓瘤患者的疗效及预后因素分析[J].中华血液学杂志, 2014, 35(3):225-230. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhxyx201403010Liang ZY, Ren HY, Cen XN, et al. Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience[J]. Chinese Journal of Hematology, 2014, 35(3):225-230. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhxyx201403010 [6] Rajkumar SV. Treatment of multiple myeloma[J]. Nat Rev Clin Oncol, 2011, 20(8):479-490. [7] Neri P, Ren L, Gratton K, et al. Bortezomib-induced "BRCA-ness" sensitizes multiple myeloma cells to PARP inhibitors[J]. Blood, 2011, 118(24):6368-6379. doi: 10.1182/blood-2011-06-363911 [8] Yuan ZG, Jin J, Huang XJ, et al. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma:an open-label, observational, multi-center study in China[J]. Chin Med J(En91), 2011, 124(19):2969-2974. http://www.cqvip.com/QK/85656X/201119/39797580.html [9] Bensinger WI, Jagannath S, Vescio R, et al. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophos-phamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frondine therapy for multiple myeloma[J]. Br J Haematol, 2010, 148(4):562-568. doi: 10.1111/j.1365-2141.2009.07981.x [10] Manoehakian R, Miller KC, Chanan-Khan AA. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma [J]. Oncologist, 2007, 12(8):978-990. doi: 10.1634/theoncologist.12-8-978 [11] 顾宏涛, 舒汩汩, 高广勋, 等.标准和减低剂量硼替佐米联合阿霉素及地塞米松治疗多发性骨髓瘤疗效比较[J].中华血液学杂志, 2013, 34(7):622-625. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhxyx201307014Gu HT, Su GG, Gao GX, et al. Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma[J]. Chinese Journal opf Hematology, 2013, 34(7):622-625. [ http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhxyx201307014 [12] Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neumpathy with bortezomib in the phase Ⅲ APEX trial in relapsed multiple myeloma:impact of a dose modification guideline[J]. Br J Haematol, 2009, 144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x [13] Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phaseⅢstudy of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma[J]. Haematologica, 2012, 97(12):1925-1928. doi: 10.3324/haematol.2012.067793 -
点击查看大图
表(4)
计量
- 文章访问数: 79
- HTML全文浏览量: 16
- PDF下载量: 3
- 被引次数: 0
下载:
